- Third quarter 2026 revenue of
$44.6 million ; adjusted EBITDA loss of approximately$0.4 million , within the Company’s guidance range of negative$1 million to positive$2 million . - Adjusted EBITDA improved approximately
$3.1 million sequentially from an adjusted EBITDA loss of$3.5 million in the second quarter of 2026, driven primarily by a 34% sequential reduction in selling and marketing expenses and reduction of overall non-clinical expenses. - GAAP net loss from continuing operations attributable to common stockholders of
$5.2 million , or$0.11 per share, compared with$8.4 million , or$0.18 per share, in the second quarter of 2026. - Total active subscribers increased 13% year-over-year to approximately 350,000.
LifeMD Pharmacy shipment volume grew 58.3% year-over-year.- Exited the quarter with
$21.9 million of cash and no debt; subsequent to quarter-end, closed on a$12.5 million senior secured term loan to replace the Company’s previous credit facility. - Entered into arrangements with both Novo Nordisk and Eli Lilly, enabling LifeMD’s pharmacy to begin dispensing self-pay branded GLP-1 medications, including Wegovy, Wegovy Pill, Ozempic, Zepbound, and Foundayo, to patients nationwide.
- Entered into an exclusive relationship with AT&T to provide its 100 million wireless and fiber customers and 110,000
U.S . employees access to LifeMD’s healthcare and pharmacy services. - Expecting fourth quarter 2026 revenue of between
$46 million and$49 million , and Adjusted EBITDA of between negative$4 million to negative$2 million .
Conference call begins at
Management Commentary
“We ended the quarter with approximately 350,000 active subscribers, up 13% from a year ago and nearly flat from the second quarter, despite spending
“Revenue of
“Our pharmacy has begun dispensing branded GLP-1 medications from Eli Lilly and Novo Nordisk. Our exclusive relationship with AT&T gives its 100 million wireless and fiber customers and 110,000
“Gross margin was approximately 82% in the quarter, compared with approximately 89% in the second quarter and 85% a year ago. The decline primarily reflects a change in presentation, not economics: under our new branded fulfillment arrangements, medications fulfilled by our own pharmacy are recognized on a gross revenue basis,” said
Third Quarter 2026 Financial Highlights
All comparisons are with the third quarter of 2025 on a continuing operations basis (excluding WorkSimpli, which was divested on
- Total revenue was
$44.6 million , compared with$47.7 million in the prior-year period, a decrease of approximately 7%. - Gross profit was
$36.4 million , compared with$40.7 million in the prior-year period. Gross margin was approximately 82%, compared with approximately 85% in the prior-year period, a decline of approximately 370 basis points, primarily reflecting the gross revenue presentation of branded medications fulfilled by our pharmacy. - Selling and marketing expenses decreased 18% year-over-year, and 34% sequentially, to
$18.5 million . - General and administrative expenses increased 6% year-over-year to
$14.7 million , reflecting added clinical capacity. - GAAP net loss from continuing operations attributable to common stockholders was
$5.2 million , or$0.11 per share, compared with a GAAP net loss from continuing operations attributable to common stockholders of$5.4 million , or$0.12 per share, in the prior-year period. - Adjusted EBITDA was a loss of approximately
$0.4 million , compared with adjusted EBITDA of approximately$2.8 million in the prior-year period. - Cash totaled
$21.9 million as ofSeptember 30, 2026 , and the Company had no debt at quarter end. - The number of active subscribers increased 13% year-over-year to approximately 350,000 at quarter end.
| ($ in 000s) | Three Months Ended | Y-o-Y | ||||||
| Key Performance Metrics | 2026 | 2025 | % Growth | |||||
| Revenue | $ | 44,625 | $ | 47,728 | -7 | % | ||
| Gross Profit | $ | 36,376 | $ | 40,666 | -11 | % | ||
| Gross Margin % | 82 | % | 85 | % | -370bpts | |||
| Adjusted EBITDA | $ | (413 | ) | $ | 2,787 | -115 | % | |
| Active Subscribers | 349,744 | 310,818 | 13 | % | ||||
Financial Guidance
For the fourth quarter of 2026, the Company expects:
- Revenue in the range of
$46 million to$49 million . - Adjusted EBITDA in the range of negative
$4 million to negative$2 million .
For the full year 2026, the Company expects (revised from previous guidance):
- Revenue in the range of
$188 million to$191 million , compared with previous guidance of$205.5 million to$212.5 million . - Adjusted EBITDA in the range of negative
$12.6 million to negative$10.6 million , compared with previous guidance of negative$6.0 million to breakeven.
Conference Call
LifeMD’s management will host a conference call today at
| Toll-free dial-in number: | (877) 270-2148 |
| International dial-in number: | +1 (412) 902-6510 |
| Conference ID: | |
A live and archived webcast will be available in the Investors section of the Company’s website at ir.lifemd.com.
About
LifeMD® is a leading virtual care company making high-quality healthcare more accessible, convenient, and affordable. Through its vertically integrated platform,
Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
Investor Contact
ir@lifemd.com
Media Contact
press@lifemd.com
Tables to Follow
| CONSOLIDATED BALANCE SHEETS | |||||||
| (Unaudited) | |||||||
| ASSETS | |||||||
| Current Assets | |||||||
| Cash | $ | 21,921,769 | $ | 36,786,318 | |||
| Receivables, net | 13,249,849 | 2,485,882 | |||||
| Product deposit | 218,690 | 320,217 | |||||
| Inventory, net | 10,348,601 | 2,773,576 | |||||
| Other current assets | 3,522,349 | 2,646,077 | |||||
| Total Current Assets | 49,261,258 | 45,012,070 | |||||
| Non-current Assets | |||||||
| Equipment, net | 1,905,154 | 2,444,717 | |||||
| Right of use assets, net | 4,622,463 | 5,267,857 | |||||
| Capitalized software, net | 10,329,573 | 10,604,946 | |||||
| Intangible assets, net | 166,583 | 262,334 | |||||
| Total Non-current Assets | 17,023,773 | 18,579,854 | |||||
| Total Assets | $ | 66,285,031 | $ | 63,591,924 | |||
| LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY | |||||||
| Current Liabilities | |||||||
| Accounts payable | $ | 37,736,899 | $ | 14,149,154 | |||
| Accrued expenses | 12,842,607 | 14,214,393 | |||||
| Current operating lease liabilities | 691,719 | 642,422 | |||||
| Deferred revenue | 10,433,507 | 10,573,442 | |||||
| Total Current Liabilities | 61,704,732 | 39,579,411 | |||||
| Long-term Liabilities | |||||||
| Non-current operating lease liabilities | 5,159,954 | 5,681,374 | |||||
| Total Liabilities | 66,864,686 | 45,260,785 | |||||
| Commitments and Contingencies | |||||||
| Stockholders’ (Deficit) Equity | |||||||
| Series A Preferred Stock, | 140 | 140 | |||||
| Common Stock, | 483,589 | 467,600 | |||||
| Additional paid-in capital | 255,443,609 | 251,455,616 | |||||
| Accumulated deficit | (256,343,292 | ) | (233,428,516 | ) | |||
| (163,701 | ) | (163,701 | ) | ||||
| Total | (579,655 | ) | 18,331,139 | ||||
| Total Liabilities and Stockholders’ (Deficit) Equity | $ | 66,285,031 | $ | 63,591,924 | |||
| CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
| (Unaudited) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Telehealth revenue, net | $ | 44,625,086 | $ | 47,727,942 | $ | 142,048,848 | $ | 146,861,697 | |||||||
| Cost of telehealth revenue | 8,249,469 | 7,061,651 | 19,605,877 | 21,627,901 | |||||||||||
| Gross profit | 36,375,617 | 40,666,291 | 122,442,971 | 125,233,796 | |||||||||||
| Expenses | |||||||||||||||
| Selling and marketing expenses | 18,500,609 | 22,563,994 | 76,411,416 | 66,988,030 | |||||||||||
| General and administrative expenses | 14,654,524 | 13,800,377 | 43,468,661 | 42,995,255 | |||||||||||
| Other operating expenses | 3,453,051 | 2,800,013 | 9,673,184 | 8,072,564 | |||||||||||
| Customer service expenses | 2,351,426 | 2,784,320 | 8,103,717 | 9,086,549 | |||||||||||
| Development costs | 1,882,508 | 1,844,269 | 5,470,005 | 5,526,379 | |||||||||||
| Total expenses | 40,842,118 | 43,792,973 | 143,126,983 | 132,668,777 | |||||||||||
| Operating loss from continuing operations | (4,466,501 | ) | (3,126,682 | ) | (20,684,012 | ) | (7,434,981 | ) | |||||||
| Interest (expense) income, net | (3,212 | ) | (260,621 | ) | 98,924 | (1,385,046 | ) | ||||||||
| Loss on debt extinguishment | - | (1,155,851 | ) | - | (1,155,851 | ) | |||||||||
| Loss from continuing operations before income taxes | (4,469,713 | ) | (4,543,154 | ) | (20,585,088 | ) | (9,975,878 | ) | |||||||
| Income tax provision | - | (31,823 | ) | - | (31,823 | ) | |||||||||
| Net loss from continuing operations | (4,469,713 | ) | (4,574,977 | ) | (20,585,088 | ) | (10,007,701 | ) | |||||||
| Net income from discontinued operations | - | 935,013 | - | 4,821,519 | |||||||||||
| Net loss | (4,469,713 | ) | (3,639,964 | ) | (20,585,088 | ) | (5,186,182 | ) | |||||||
| Net income attributable to noncontrolling interests of discontinued operations | - | 249,462 | - | 1,286,382 | |||||||||||
| Net loss attributable to | (4,469,713 | ) | (3,889,426 | ) | (20,585,088 | ) | (6,472,564 | ) | |||||||
| Preferred stock dividends | (776,563 | ) | (776,563 | ) | (2,329,688 | ) | (2,329,688 | ) | |||||||
| Net loss attributable to | $ | (5,246,276 | ) | $ | (4,665,989 | ) | $ | (22,914,776 | ) | $ | (8,802,252 | ) | |||
| Basic (loss) earnings per share attributable to | |||||||||||||||
| Continuing operations | $ | (0.11 | ) | $ | (0.12 | ) | $ | (0.48 | ) | $ | (0.28 | ) | |||
| Discontinued operations | - | 0.01 | - | 0.08 | |||||||||||
| Basic loss per share | $ | (0.11 | ) | $ | (0.10 | ) | $ | (0.48 | ) | $ | (0.20 | ) | |||
| Diluted (loss) earnings per share attributable to | |||||||||||||||
| Continuing operations | $ | (0.11 | ) | $ | (0.12 | ) | $ | (0.48 | ) | $ | (0.28 | ) | |||
| Discontinued operations | - | 0.01 | - | 0.08 | |||||||||||
| Diluted loss per share | $ | (0.11 | ) | $ | (0.10 | ) | $ | (0.48 | ) | $ | (0.20 | ) | |||
| Weighted average number of common shares outstanding: | |||||||||||||||
| Basic | 48,182,152 | 46,162,625 | 47,772,180 | 44,575,553 | |||||||||||
| Diluted | 48,182,152 | 46,162,625 | 47,772,180 | 44,575,553 | |||||||||||
| CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||||||||||
| (Unaudited) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| CASH FLOWS FROM OPERATING ACTIVITIES | |||||||||||||||
| Net loss | $ | (4,469,713 | ) | $ | (3,639,964 | ) | $ | (20,585,088 | ) | $ | (5,186,182 | ) | |||
| Less: Net income from discontinued operations | - | 935,013 | - | 4,821,519 | |||||||||||
| Net loss from continuing operations | (4,469,713 | ) | (4,574,977 | ) | (20,585,088 | ) | (10,007,701 | ) | |||||||
| Adjustments to reconcile net loss from continuing operations to net cash (used in) provided by operating activities: | |||||||||||||||
| Amortization of debt discount | - | 33,481 | - | 234,369 | |||||||||||
| Amortization of capitalized software | 1,727,834 | 1,597,030 | 5,116,366 | 4,712,732 | |||||||||||
| Amortization of intangibles | 31,917 | 31,917 | 95,751 | 62,084 | |||||||||||
| Loss on debt extinguishment | - | 1,155,851 | - | 1,155,851 | |||||||||||
| Depreciation of fixed assets | 301,049 | 253,031 | 883,294 | 583,915 | |||||||||||
| Noncash operating lease expense | 217,495 | 217,495 | 645,394 | 743,207 | |||||||||||
| Stock compensation expense | 1,684,445 | 3,198,036 | 3,923,462 | 7,841,178 | |||||||||||
| Changes in Assets and Liabilities | |||||||||||||||
| Receivables | (9,507,862 | ) | (10,338 | ) | (10,763,967 | ) | 2,618,396 | ||||||||
| Product deposit | 25,069 | (119,518 | ) | 101,527 | (329,755 | ) | |||||||||
| Inventory | (7,392,457 | ) | (181,027 | ) | (7,575,025 | ) | (635,024 | ) | |||||||
| Other current assets | (1,035,546 | ) | (1,382,528 | ) | (876,272 | ) | (558,239 | ) | |||||||
| Operating lease liabilities | (165,451 | ) | (23,535 | ) | (472,123 | ) | (171,841 | ) | |||||||
| Deferred revenue | (357,714 | ) | (2,322,589 | ) | (139,935 | ) | (4,864,738 | ) | |||||||
| Accounts payable | 19,579,987 | (4,591,851 | ) | 23,587,745 | 3,896,078 | ||||||||||
| Accrued expenses | (1,588,687 | ) | 4,529,660 | (1,371,786 | ) | (1,109,939 | ) | ||||||||
| Net cash (used in) provided by operating activities of continuing operations | (949,634 | ) | (2,189,862 | ) | (7,430,657 | ) | 4,170,573 | ||||||||
| Net cash provided by operating activities of discontinued operations | - | 2,042,726 | - | 7,390,125 | |||||||||||
| Net cash (used in) provided by operating activities | (949,634 | ) | (147,136 | ) | (7,430,657 | ) | 11,560,698 | ||||||||
| CASH FLOWS FROM INVESTING ACTIVITIES | |||||||||||||||
| Cash paid for capitalized software costs | (1,322,921 | ) | (1,937,544 | ) | (4,840,993 | ) | (5,884,672 | ) | |||||||
| Purchase of equipment | (170,728 | ) | (785,748 | ) | (343,731 | ) | (1,679,963 | ) | |||||||
| Net cash used in investing activities of continuing operations | (1,493,649 | ) | (2,723,292 | ) | (5,184,724 | ) | (7,564,635 | ) | |||||||
| Net cash used in investing activities of discontinued operations | - | (871,188 | ) | - | (2,596,766 | ) | |||||||||
| Net cash used in investing activities | (1,493,649 | ) | (3,594,480 | ) | (5,184,724 | ) | (10,161,401 | ) | |||||||
| CASH FLOWS FROM FINANCING ACTIVITIES | |||||||||||||||
| Repayment of debt instruments | - | (16,667,433 | ) | - | (18,719,721 | ) | |||||||||
| Sale of common stock under ATM, net | - | 8,721,717 | - | 8,721,717 | |||||||||||
| Preferred stock dividends | (776,563 | ) | (776,563 | ) | (2,329,688 | ) | (2,329,688 | ) | |||||||
| Cash proceeds from exercise of warrants | - | 464,950 | - | 464,950 | |||||||||||
| Cash proceeds from exercise of options | - | 5,950 | 80,520 | 5,950 | |||||||||||
| Net cash used in financing activities of continuing operations | (776,563 | ) | (8,251,379 | ) | (2,249,168 | ) | (11,856,792 | ) | |||||||
| Net cash used in financing activities of discontinued operations | - | (449,539 | ) | - | (761,658 | ) | |||||||||
| Net cash used in financing activities | (776,563 | ) | (8,700,918 | ) | (2,249,168 | ) | (12,618,450 | ) | |||||||
| Net decrease in cash | (3,219,846 | ) | (12,442,534 | ) | (14,864,549 | ) | (11,219,153 | ) | |||||||
| Cash at beginning of period | 25,141,615 | 36,228,305 | 36,786,318 | 35,004,924 | |||||||||||
| Cash at end of period | 21,921,769 | 23,785,771 | 21,921,769 | 23,785,771 | |||||||||||
| Less: Cash of discontinued operations at end of period | - | 2,838,484 | - | 2,838,484 | |||||||||||
| Cash of continuing operations at end of period | $ | 21,921,769 | $ | 20,947,287 | $ | 21,921,769 | $ | 20,947,287 | |||||||
| Cash paid for interest and taxes | |||||||||||||||
| Cash paid during the period for interest | $ | - | $ | 241,464 | $ | - | $ | 1,461,032 | |||||||
| Cash paid during the period for taxes | $ | - | $ | 14,617 | $ | 361,230 | $ | 482,471 | |||||||
| Non-cash investing and financing activities | |||||||||||||||
| Cashless exercise of options | $ | - | $ | 253 | $ | - | $ | 1,315 | |||||||
| Cashless exercise of warrants | $ | 3,204 | $ | - | $ | 3,204 | $ | 3,901 | |||||||
| Stock issued for debt conversion | $ | - | $ | - | $ | - | $ | 1,000,000 | |||||||
| Stock issued for asset acquisition | $ | - | $ | - | $ | - | $ | 303,000 | |||||||
About the Use of Non-GAAP Financial Measures
To supplement our financial information presented in accordance with GAAP, we use adjusted EBITDA as a non-GAAP financial measure to clarify and enhance an understanding of past performance. We believe that the presentation of this financial measure enhances an investor’s understanding of our financial performance. We further believe that this financial measure is a useful financial metric to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors.
Adjusted EBITDA is defined as net loss attributable to
We believe the above financial measure is commonly used by investors to evaluate our performance and that of our competitors. However, our use of the term adjusted EBITDA may vary from that of others in our industry. Adjusted EBITDA should not be considered as an alternative to net loss before taxes, net loss per share, operating loss or any other performance measures derived in accordance with GAAP as measures of performance.
| Reconciliation of Net Loss Attributable to | |||||||||||||||
| (in whole numbers, unaudited) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Net loss attributable to | $ | (5,246,276 | ) | $ | (4,665,989 | ) | $ | (22,914,776 | ) | $ | (8,802,252 | ) | |||
| Interest (income) expense, net | 3,212 | 227,140 | (98,924 | ) | 1,150,677 | ||||||||||
| Depreciation and amortization expense | 2,060,800 | 1,881,978 | 6,095,411 | 5,358,731 | |||||||||||
| Amortization of debt discount | - | 33,481 | - | 234,369 | |||||||||||
| Loss on debt extinguishment | - | 1,155,851 | - | 1,155,851 | |||||||||||
| Financing transactions expense | - | 97,699 | - | 97,699 | |||||||||||
| Litigation costs (a) | 64,328 | 959,803 | 1,112,269 | 1,699,462 | |||||||||||
| Severance and restructuring costs | 243,885 | - | 992,879 | 102,417 | |||||||||||
| Acquisitions expenses | - | (231,571 | ) | - | 1,783,206 | ||||||||||
| Insurance acceptance readiness | - | 8,190 | - | 183,330 | |||||||||||
| Taxes | - | 31,823 | - | 31,823 | |||||||||||
| Preferred stock dividends | 776,563 | 776,563 | 2,329,688 | 2,329,688 | |||||||||||
| Stock compensation expense | 1,684,445 | 3,198,036 | 3,923,462 | 7,841,178 | |||||||||||
| Net income from discontinued operations | - | (935,013 | ) | - | (4,821,519 | ) | |||||||||
| Net income attributable to noncontrolling interests of discontinued operations | - | 249,462 | - | 1,286,382 | |||||||||||
| Adjusted EBITDA | $ | (413,043 | ) | $ | 2,787,452 | $ | (8,559,991 | ) | $ | 9,631,041 | |||||
| (a) For the three and nine months ended | |||||||||||||||
Source: 